White atractylodes 白朮
Pharmaceutical nameAtractylodis Rhizoma Alba
The three axes are assessed independently and are never combined into a single score.
KTKP records the origin species as Atractylodes ovata (Thunb.) DC. (= Atractylodes macrocephala). It has not yet been cross-checked against the Korean Pharmacopoeia, so the identification confidence is not raised to an official code mapping. The same drug appears under 2 records as name variants. The name most used for this taxon in current literature is Atractylodes macrocephala. The nomenclatural discussion for this herb was flagged for correction during verification; only the verified facts are shown here, with the details in docs/HERB_NAME_RESEARCH.md.
Tradition · what the text describes
탕액편
The sub-section within this volume has not been verified against the original text yet.
The KTKP traditional materia medica record (M0001486) gives the origin species as Atractylodes ovata (Thunb.) DC. (= Atractylodes macrocephala), the part used as 뿌리, and the properties as 감고(甘苦), 무독(無毒), 온(溫). It lists 비(脾), 위(胃) as the channels entered. The same record cites the Donguibogam (1613) as the source for its indications.
Properties & channel entry: 감고(甘苦), 무독(無毒), 온(溫) · 비(脾), 위(胃)
Source species: Atractylodes ovata (Thunb.) DC. (= Atractylodes macrocephala) (뿌리)
Modern · documented evidence
(no indication derived — herb-name-only search)evidence for this indication
- No indication is specified. A and B grades cannot be assigned until the query is narrowed to a specific indication.
- No indication could be derived: no condition appears on two or more registered trials for this herb.
Literature
SR 14 · RCT 6 · preclinical 218
These counts come from a herb-name-only search (14 systematic reviews, 6 RCTs). Without a specific indication they show how much the herb has been studied, not what it works for.
Query used
We publish the exact query behind these counts so you can reproduce them yourself.
SRC:MED AND ((TITLE_ABS:"Atractylodes macrocephala"))- Expression of Concern: Protection of LPS-induced intestinal injury in goslings by polysaccharide of Atractylodes macrocephala Koidz based on 16S rRNA and metabolomics analysis. (2026 · Journal Article; Expression of Concern)
- Atractylodes Macrocephala Polysaccharides Regulate the Innate Immunity of Colorectal Cancer Cells by Modulating the TLR4 Signaling Pathway [Retraction]. (2026 · Retraction of Publication; Journal Article; Retraction Notice)
- Corrigendum to "A novel composite hydrogel containing natural polysaccharides derived from Atractylodes macrocephala Koidz. for diabetic wound healing" [J. Ethnopharmacol. 356 (2026) 120844]. (2027 · Published Erratum)
- Study on the mechanism of Atractylodes macrocephala extract regulating mitochondrial endoplasmic reticulum stress through PI3K/Akt signaling pathway to reverse epithelial-mesenchymal transition in uterine fibroids. (2026 · Journal Article)
- Geographic transplantation promotes the growth of Atractylodes macrocephala by restructuring the rhizosphere microbial community. (2026 · research-article; Journal Article)
- Atractylodes macrocephala Koidz. polysaccharides alleviate liver fibrosis in association with suppression of cGAS-STING signaling and mitochondrial apoptosis. (2026 · Journal Article)
- Atractylodes macrocephala (2006 · Review)
- Atramacronins A-P, eudesmane-type sesquiterpenoid dimers from Atractylodes macrocephala with anti-hepatocellular carcinoma activities. (2026 · Journal Article)
- An Inulin-Type Atractylodes Macrocephala Polysaccharide Alleviates Weightlessness-Induced Bone Loss in Association with the Nrf2/HO-1 Pathway. (2026 · Journal Article)
- Atractylodes macrocephala polysaccharide AMP1-1 ameliorates weightless-induced cognitive dysfunction via the microbiota-gut-brain axis. (2026 · Journal Article)
Clinical trials
- NCT07757061 — COMPLETED · NA
- NCT04767620 — UNKNOWN · PHASE2
- NCT04601792 — UNKNOWN · PHASE4
- NCT05229029 — UNKNOWN · PHASE2
- NCT05640570 — COMPLETED · PHASE2
- NCT02488252 — UNKNOWN · PHASE2, PHASE3
- NCT03375580 — UNKNOWN · NA
- NCT07698574 — NOT_YET_RECRUITING · NA
- NCT04935073 — UNKNOWN · PHASE3
- NCT05631782 — COMPLETED · EARLY_PHASE1
Safety
auto-proposed · unreviewed
- 10 adverse-event or toxicity record(s) were found. This only flags that literature exists — read the abstracts to decide between "caution" and "harm confirmed".
- 1 interaction-related record(s) are retrievable. This flags that literature exists — it is not an interaction checker (§3.4).
- The KTKP record states the following traditional contraindication: 성(性)이 온조(溫燥)하여 다복(多服)하면 상음(傷陰)의 우려가 있으며 음허내열(陰虛內熱) 또는 진액휴모조갈(津液虧耗燥渴)의 경우에는 기(忌)한다.
Adverse-event and toxicity literature
This is not a finding of harm — it lists literature that is retrievable. Read the papers to decide.
- Protective effects of Atractylodes macrocephala polysaccharides on acetaminophen-induced liver injury. (2025 · research-article; Journal Article)
- Differential toxic phenotypes and liver injury induced by Atractylenolides (I, II, and III): Insights from zebrafish (Danio rerio) models and network toxicology. (2026 · Journal Article)
- Efficacy of Yupingfeng powder in the treatment of bronchial asthma in adults: a systematic review and meta-analysis. (2026 · Systematic Review; systematic-review; Journal Article)
- Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. (2023 · review-article; Review; Journal Article)
- Strychni Semen Combined with Atractylodes Macrocephala Koidz Attenuates Rheumatoid Arthritis by Regulating Apoptosis. (2024 · Journal Article)
Interaction literature
This lists literature that is retrievable — it is not a judgement that an interaction exists. Read the papers to decide.
- Strong Specific Inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide I and III. (2016 · Research Support, Non-U.S. Gov't; Journal Article)